Filing Analysis
Champions Oncology, Inc. issued an 8-K to announce the release of its audited financial results for the fiscal year ended April 30, 2026.
📋 Key Facts
- Company released audited financial results for the fiscal year ending April 30, 2026.
- The announcement was made via press release on July 27, 2026.
- The filing is an Item 2.02 report regarding Results of Operations and Financial Condition.
Champions Oncology announced the resignation of Dr. Philip Breitfeld from its Board of Directors and the concurrent appointment of Dr. Brian Alexander to fill the vacancy. Dr. Alexander brings extensive experience in oncology and data science from leadership roles at Valo Health, Roche/Genentech, and Foundation Medicine.
📋 Key Facts
- Dr. Philip Breitfeld resigned from the Board of Directors on March 24, 2026.
- Dr. Brian Alexander was appointed as a director on March 24, 2026.
- Dr. Alexander is the current CEO of Valo Health Inc. and a CEO-Partner at Flagship Pioneering.
- Dr. Alexander's previous roles include CEO of Foundation Medicine and Senior Vice President for Research & Development at Roche/Genentech.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Champions Oncology, Inc. announced its unaudited financial results for the third fiscal quarter ended January 31, 2026. The results were disclosed via a press release on March 12, 2026, and filed under Item 2.02.
📋 Key Facts
- The filing reports financial results for the third fiscal quarter ended January 31, 2026.
- The announcement was made on March 12, 2026.
- The company utilized Item 2.02 (Results of Operations and Financial Condition) for the disclosure.
- A press release was attached as Exhibit 99.1.
Champions Oncology, Inc. issued an 8-K to announce its unaudited financial results for the second quarter ended October 31, 2025.
📋 Key Facts
- Report date: December 15, 2025
- Reporting period: Second quarter ended October 31, 2025
- The filing contains unaudited financial results via a press release (Exhibit 99.1)
- Information under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act
Champions Oncology, Inc. held its Annual Meeting of Stockholders on October 16, 2025. The meeting resulted in the election of seven directors and the ratification of EisnerAmper LLP as the independent accounting firm.
📋 Key Facts
- Annual Meeting of Stockholders held on October 16, 2025.
- Seven director nominees (Ronnie Morris, Joel Ackerman, Robert Brainin, David Sidransky, Daniel Mendelson, Scott R. Tobin, and Philip Breitfeld) were elected to one-year terms.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending April 30, 2026.
- A non-binding advisory resolution regarding executive officer compensation was approved.
Champions Oncology, Inc. filed an 8-K to announce the release of its unaudited financial results for the first quarter ended July 31, 2025.
📋 Key Facts
- Report date: September 15, 2025
- Reporting period: First quarter ended July 31, 2025
- Nature of filing: Unaudited financial results via press release (Exhibit 99.1)
Champions Oncology, Inc. issued an 8-K to announce the release of its audited financial results for the fiscal year ended April 30, 2025.
📋 Key Facts
- Company released audited financial results for the fiscal year ended April 30, 2025.
- The announcement was made via press release on July 23, 2025.
- Report filed under Item 2.02 (Results of Operations and Financial Condition).
Champions Oncology, Inc. announced a leadership transition where Robert Brainin will become CEO effective August 25, 2025, while Dr. Ronnie Morris transitions to Executive Chairman.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Robert Brainin appointed as CEO, effective August 25, 2025.
- Mr. Brainin previously served as a Director since February 2021 and most recently as CBO/EVP at Veracyte.
- CEO compensation includes $500,000 annual base salary and a 75% target discretionary bonus.
- Equity package includes 225,000 options (4-year vesting) and 475,000 performance-based options.
- Dr. Ronnie Morris to transition to Executive Chairman on August 25, 2025.
- Joel Ackerman will transition from Chairman of the Board to a Director role.
Champions Oncology, Inc. filed an 8-K to announce the issuance of a press release containing unaudited financial results for its third quarter ended January 31, 2025.
📋 Key Facts
- Reporting period: Third quarter ended January 31, 2025.
- Filing date: March 11, 2025.
- The filing includes unaudited financial results via an attached press release (Exhibit 99.1).
Champions Oncology, Inc. issued an 8-K to announce the release of its unaudited financial results for the second quarter ended October 31, 2024.
📋 Key Facts
- The filing pertains to the second quarter ended October 31, 2024.
- Financial results released are unaudited.
- The announcement was made via a press release dated December 11, 2024.
Champions Oncology, Inc. held its Annual Meeting of Stockholders on October 14, 2024. The meeting resulted in the election of seven directors and the ratification of EisnerAmper LLP as the independent accounting firm.
📋 Key Facts
- Annual Meeting of Stockholders held on October 14, 2024.
- Seven director nominees were elected to one-year terms expiring at the 2025 Annual Meeting.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for the fiscal year ending April 30, 2025.
- A non-binding advisory resolution regarding executive compensation was approved.
Champions Oncology, Inc. announced the unexpected passing of its President, Mr. Brady Davis, who had served in the role since October 2023.
🚩 Red Flags
- Sudden and unexpected departure of a key executive (President) due to death creates immediate leadership vacuum and operational uncertainty.
📋 Key Facts
- President Brady Davis passed away unexpectedly during the week of October 3, 2024.
- Mr. Davis had been serving as President since October 2023.
- The announcement was made via an 8-K filing on October 3, 2024.
Champions Oncology, Inc. issued an 8-K to announce the release of its unaudited financial results for the first quarter ended July 31, 2024.
📋 Key Facts
- The filing relates to the company's unaudited financial results for Q1 ending July 31, 2024.
- Results were announced via press release on September 11, 2024.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
Champions Oncology, Inc. has issued a press release regarding its audited financial results for the fiscal year ended April 30, 2024.
📋 Key Facts
- The filing relates to the Company's audited financial results for the fiscal year ending April 30, 2024.
- The report was filed on July 18, 2024.
- The announcement is accompanied by a press release (Exhibit 99.1).
Champions Oncology, Inc. issued an 8-K to announce the release of its unaudited financial results for the third quarter ended January 31, 2024.
📋 Key Facts
- Report date: March 12, 2024
- Reporting period: Third quarter ended January 31, 2024
- Nature of filing: Unaudited financial results announcement via press release (Exhibit 99.1)